AdAlta Limited (1AD.AX)
AUD 0.01
(-16.67%)
AUD 0.01
(-16.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -5.38 Million AUD | -10.93% |
| 2023 | -4.85 Million AUD | 19.96% |
| 2022 | -6.06 Million AUD | -7.69% |
| 2021 | -5.62 Million AUD | 6.29% |
| 2020 | -6 Million AUD | -1.49% |
| 2019 | -5.91 Million AUD | -53.52% |
| 2018 | -3.85 Million AUD | -36.09% |
| 2017 | -2.83 Million AUD | -143.54% |
| 2016 | -1.16 Million AUD | 11.07% |
| 2015 | -1.3 Million AUD | -4.73% |
| 2014 | -1.24 Million AUD | -64.25% |
| 2013 | -760.3 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -5.38 Million AUD | -10.93% |
| 2024 Q4 | -2.36 Million AUD | 0.0% |
| 2024 Q2 | -3.01 Million AUD | 0.0% |
| 2023 Q4 | -2.02 Million AUD | 0.0% |
| 2023 FY | -4.85 Million AUD | 19.96% |
| 2023 Q2 | -2.82 Million AUD | 0.0% |
| 2022 Q4 | -2.4 Million AUD | 0.0% |
| 2022 Q2 | -3.65 Million AUD | 0.0% |
| 2022 FY | -6.06 Million AUD | -7.69% |
| 2021 Q4 | -1.11 Million AUD | 0.0% |
| 2021 Q2 | -4.51 Million AUD | 0.0% |
| 2021 FY | -5.62 Million AUD | 6.29% |
| 2020 Q2 | -6 Million AUD | 0.0% |
| 2020 Q4 | -1956.00 AUD | 0.0% |
| 2020 FY | -6 Million AUD | -1.49% |
| 2019 FY | -5.91 Million AUD | -53.52% |
| 2019 Q2 | -3.62 Million AUD | 0.0% |
| 2019 Q4 | -2.29 Million AUD | 0.0% |
| 2018 Q4 | -445.32 Thousand AUD | 0.0% |
| 2018 Q2 | -3.4 Million AUD | 0.0% |
| 2018 FY | -3.85 Million AUD | -36.09% |
| 2017 Q2 | -2.26 Million AUD | 0.0% |
| 2017 FY | -2.83 Million AUD | -143.54% |
| 2017 Q4 | -566.82 Thousand AUD | 0.0% |
| 2016 Q1 | -344.2 Thousand AUD | 0.0% |
| 2016 Q4 | -474.64 Thousand AUD | 0.0% |
| 2016 Q2 | -688.41 Thousand AUD | -100.0% |
| 2016 FY | -1.16 Million AUD | 11.07% |
| 2015 FY | -1.3 Million AUD | -4.73% |
| 2014 FY | -1.24 Million AUD | -64.25% |
| 2013 FY | -760.3 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acrux Limited | -5.8 Million AUD | 7.22% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -19.492% |
| Biome Australia Limited | -1.67 Million AUD | -222.193% |
| BTC Health Limited | 1.05 Million AUD | 609.934% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 57.052% |
| CSL Limited | 2.64 Billion AUD | 100.204% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 87.286% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 115.101% |
| Noxopharm Limited | -3.57 Million AUD | -50.394% |
| PharmAust Limited | -9.03 Million AUD | 40.422% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 15.604% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 34.678% |
| PYC Therapeutics Limited | -37.72 Million AUD | 85.736% |
| Race Oncology Limited | -13.81 Million AUD | 61.06% |
| Starpharma Holdings Limited | -8.16 Million AUD | 34.093% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 177.267% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 61.201% |
| Memphasys Limited | -4.44 Million AUD | -21.145% |
| Nyrada Inc. | -1.38 Million AUD | -288.195% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -270.804% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 203.267% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -123.365% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 85.285% |
| Patrys Limited | -3.53 Million AUD | -52.05% |
| Dimerix Limited | -17.07 Million AUD | 68.485% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 103.426% |
| Orthocell Limited | -7.18 Million AUD | 25.062% |
| Imugene Limited | -149.68 Million AUD | 96.405% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 44.778% |
| Immutep Limited | -39.89 Million AUD | 86.512% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 38.472% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 71.86% |
| Nanollose Limited | -1.15 Million AUD | -365.285% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -227.765% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 1759.81% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -87.873% |
| Biotron Limited | -3.43 Million AUD | -56.59% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 88.777% |
| Tissue Repair Ltd | -4.13 Million AUD | -30.042% |
| AnteoTech Limited | -8.88 Million AUD | 39.404% |
| Hexima Limited | -933.87 Thousand AUD | -476.231% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 90.825% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 69.531% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -56.589% |
| Actinogen Medical Limited | -13.04 Million AUD | 58.746% |
| Immuron Limited | -6.93 Million AUD | 22.426% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 1.792% |